The pharmacogenomics approach about MTX-induced leukoencephalopathy

The pharmacogenomics approach about MTX-induced leukoencephalopathy - The pharmacogenomics of MTX-induced leukoencephalopathy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000020127

Enrollment

Registered

2015-12-09

Start date

2015-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

leukoencephalopthy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who were investigated CNS by MRI after chemotherapy or before bone marrow transplantation

Exclusion criteria

Exclusion criteria: Not investigated CNS by MRI

Design outcomes

Primary

Measure	Time frame
The association MTX-induced leukoencephalopathy and gene after chemotherapy	—

Countries

Japan

Contacts

Public ContactTsujimoto Shinichi

Yokohama city university Department of Pediatrics

t156046c@yokohama-cu.ac.jp045-787-2800

Outcome results